Open AccessThe high cost burden of third- to fifth-line treatments for multiple myeloma: unsustainable and unaffordable
Author(s) -
Chelsee Jensen
Publication year - 2021
Publication title -
journal of managed care and specialty pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.126
H-Index - 63
eISSN - 2376-1032
pISSN - 2376-0540
DOI - 10.18553/jmcp.2021.27.9.1321
Subject(s) - medicine , medline , family medicine , political science , law
DISCLOSURES : No funding was provided for the writing of this commentary. In this commentary, the author refers to CivicaRx, for which Mayo Clinic is a founding member. As an employee of Mayo Clinic, the author does not have any direct financial relationship with or support from CivicaRx.